



IN THE CLAIMS

The following listing replaces all prior listings and versions of the claims. The deletion of subject matter from any claims or the cancellation of any claim is effected without prejudice.

1. (Currently Amended) A method for the treatment, ~~amelioration and/or prophylaxis~~ of a neurological condition which comprises the administration of an effective amount of a compound of Formula [[I]] Ia:



I



Ia

in which

R is O or S;

each R¹ is independently halo;

[[R¹]] each R⁸ is independently selected from H, optionally substituted alkyl, optionally substituted alkenyl[[;]], optionally substituted alkynyl[[;]], optionally substituted aryl[[;]], optionally substituted heterocyclyl[[;]], ~~an antioxidant; a targeting moiety~~; CN[[;]], halo[[;]],

CF₃[[;]], SO₃H[[;]], [[and]] OR², [[SR²]] SR⁷, SOR², SO₂R², NR²R³, (CH₂)_nNR²R³, HCNOR², HCNNR²R³, CONR²R³, CSNR²R³, NCOR², NCSR², COR², CO₂R², CSR² [[or]]and SO₂NR²R³ in which R² and R³ are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl[[.]];

R⁷ is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted heterocyclyl; an antioxidant or a targeting moiety and

n is an integer of 1 to 10; and

~~X is independently selected from CH, CO, N and NH;~~

~~Z is independently selected from CH, CO, N, NH and O;~~

~~Y is absent or together with the ring to which it is attached forms a 5 or 6 membered optionally substituted aryl or a 5 or 6 membered optionally substituted heterocyclyl;~~

m is an integer from 1 to 3; and 1 or 2;

~~p is an integer from 1 to 4,~~


~~salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof to a subject in need thereof, or pharmaceutically salts thereof or tautomers of compounds of Formula Ia,~~

wherein aryl is a 5 or 6-membered aryl group; heterocyclyl is a saturated or unsaturated 3 to 6-membered heterocyclyl containing at least one ring heteroatom selected from N, O and S,


and the optional substituent is C₁₋₆ alkyl, CF₃, F, Cl, I, cyano, C₁₋₆ alkoxy, aryl, heterocyclyl, amino or C₁₋₆ alkylamino, with the provisos that:

~~(i) —at least one of X and Z is other than CH; and~~


(ii) ~~phanquinone or tautomers thereof are excluded i. e., when R is O, R¹ at position 7 is OH, X is CH and Y is absent, then Z is not~~




(iii) (1) ~~when R is O, Y is absent, Z is CH, X is CH other than at position 3~~
~~where X is N, m is 2 and R¹ is~~



at position 3, then R¹ at position 2 is not



or













(iv) ~~eliquinol, i.e., when R is O, Y is absent, Z and X are CH and m is 2, then R¹ at position 5 is not chloro and R¹ at position 7 is not iodo.~~

(2) R¹ is located at position 5 or 7 or both positions 5 and 7 of the ring.


2.-8. (Cancelled)

9. (Withdrawn-Currently Amended) A method according to ~~any one of claims 1 to 8~~ Claim 1, in which the compound of ~~Formula I~~ is as follows:







1064




1065




1053




1045




1070






1063



1069



1048



1026

10. (Withdrawn-Currently Amended) ~~[[A]] The method according to any one of claims 1 to 9~~ Claim 1, in which the neurological condition is a neurodegenerative disorder.

11. (Withdrawn -Currently Amended) ~~[[A]]The method according to Claim 10, in which the neurodegenerative~~ disorder is neurodegenerative amyloidosis.

12. (Withdrawn -Currently Amended) ~~[[A]]The method according to Claim 10 or Claim 11,~~ in which the neurodegenerative disorder is sporadic or familial Alzheimer's disease, amyotrophic lateral sclerosis, cataract, Parkinson's disease, Creutzfeldt-Jacob disease and its new variant associated with "mad cow" disease, Huntington's disease, dementia with Lewy body formation, multiple system atrophy, Hallerboden-Spatz disease, diffuse Lewy body disease, fatal familial insomnia, Gertsmann Straussler Sheinker disease, hereditary cerebral haemorrhage with

amyloidosis-Dutch type, multiple sclerosis, tauopathies, motor neuron disease or prion diseases.

13. (Withdrawn -Currently Amended) [[A]]The method according to Claim 12, in which the neurodegenerative disorder is Parkinson's disease.

14. (Withdrawn -Currently Amended) [[A]]The method according to ~~any one of Claims~~ Claim 10 [[to 12]], in which the neurodegenerative disorder is an A β -related condition.

15. (Withdrawn -Currently Amended) [[A]]The method according to Claim 14, in which the A β -related condition is Alzheimer's disease or dementia associated with Down syndrome or one of several forms of autosomal dominant forms of familial Alzheimer's disease.

16. (Withdrawn -Currently Amended) [[A]]The method according to ~~any one of the preceding claims~~ Claim 1 which slows, reduces or arrests the cognitive decline of the subject.



17. (Withdrawn -Currently Amended) [[A]]The method according to ~~any one of the preceding claims~~ Claim 1, which further comprises separate, sequential or simultaneous administration of another medicament.

18. (Withdrawn -Currently Amended) [[A]]The method according to Claim 17, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

19. (Withdrawn -Currently Amended) ~~[[A]]The method according to any one of the preceding claims Claim 1~~, in which the compound of formula I is administered orally, topically or parenterally.

20.-21. (Cancelled)

22. (Currently Amended) A compound of Formula Ia



in which

R is O or S;

each R¹ is independently halo;

[[R¹]] each R⁸ is independently selected from H, optionally substituted alkyl, optionally

substituted alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted heterocyclyl; CN; halo; CF₃; SO₃H; [[and]] OR², [[SR⁴,]] SR⁷, SOR², SO₂R², NR²R³, (CH₂)_nNR²R³, HCNOR², HCNNR²R³, CONR²R³, CSNR²R³, NCOR², NCSR², COR², CO₂R², CSR² [[or]]and SO₂NR²R³, in which R² and R³ are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heterocyclyl, ~~and n is an integer of 1 to 10;~~

[[R⁴]]R⁷ is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted heterocyclyl;

n is an integer of 1 to 10 and

~~m is an integer from 1 to 3; and q is 1 or 2;~~


or pharmaceutically acceptable salts thereof or tautomers of compounds of Formula Ia,

wherein aryl is a 5 or 6-membered aryl group; heterocyclyl is a saturated or unsaturated 3 to 6-membered heterocyclyl containing at least one heteroatom selected from N, O and S,


and the optional substituent is C₁₋₆ alkyl, CF₃, F, Cl, I, cyano, C₁₋₆ alkoxy, aryl, heterocyclyl, amino or C₁₋₆ alkylamino, with the provisos that:

(1) when R is O,


m is 2 and R¹ is



at position 3, then R¹ at position 2 is not



or



(2) R^1 is located at position 5 or 7 or both positions 5 and 7 of the ring [[and is halo]].

23.-25. (Cancelled)



26. (Previously Presented) A pharmaceutical or veterinary composition comprising the compound of formula Ia according to Claim 22 and a pharmaceutically or veterinarily acceptable carrier.

27. (Original) A composition according to Claim 26 which further comprises another medicament.

28. (Original) A composition according to Claim 27, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

29.-33. (Cancelled)

34. (Withdrawn –Currently Amended) A compound of the Formula:




35. (Previously Presented) The compound according to Claim 22 in which R is O.
36. (Currently Amended) The compound according to Claim 22 in which $[[R^1]] \underline{R}^8$ is halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkyl, OR^2 , SR^4 , $(CH_2)_nNR^2R^3$, $CONR^2R^3$ or $NCOR^2$.
37. (Currently Amended) The compound according to Claim 22 in which $[[R^1]] \underline{R}^8$ is F, I, Cl, optionally substituted phenyl, an optionally substituted unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{1-6} alkoxy, optionally substituted thio, $CH_2NR^4R^5$ in which R^4 and R^5 are independently selected from H and C_{1-4} alkyl or $CONH(CH_2)_2R^6$ in which R^6 is optionally substituted heterocyclyl.
38. (Currently Amended) The compound according to Claim 22 wherein $[[R^1]] \underline{R}^8$ is independently selected from halo, optionally substituted heterocyclyl, optionally substituted

alkyl, or $(\text{CH}_2)_n\text{NR}^2\text{R}^3$.

39. (Currently Amended) The compound according to Claim 22, wherein $[[\text{R}^1]] \text{R}^8$ is chlorine, optionally substituted phenyl, C_{2-6} cycloalkyl, $(\text{CH}_2)\text{NR}^4\text{R}^5$, wherein R^4 and R^5 are independently selected from H and C_{1-4} alkyl is optionally substituted phenyl.

40. (Previously Presented) The compound according to Claim 22 having the formula:



41. (Previously Presented) The compound according to Claim 22 wherein Cl is at position 5 or 7 of the ring.

42. (Previously Presented) The compound according to Claim 22 in which halo is at positions 5 and 7 of the ring.

43. (Previously Presented) The compound according to Claim 22 wherein Cl is at position 5 and 7 of the ring.